Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...

Pfizer's head of digital devices says the industry is close to a 'revolution' in using measures from wearables in clinical ...

Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia – a life-threatening metabolic syndrome caused by the underlying disease with no ...

CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer ...

Operator Good day, everyone, and welcome to Pfizer's third quarter 2024 earnings conference call. Today's call is being ...

Pfizer Inc. (NYSE:PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary ...

On behalf of the Pfizer team, thank you for joining us ... We had a Phase II readout of ponsegromab, which is another in-house discovered and developed by us. We are encouraged by the potential ...

Ponsegromab is under clinical development by Pfizer and currently in Phase II for Congestive Heart Failure (Heart Failure). According to... Likelihood of Approval and Phase Transition Success Rate ...